Literature DB >> 23747486

Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.

Yosuke Suzuki1, Issei Tokimatsu, Yuhki Sato, Kanako Kawasaki, Yukie Sato, Tomomi Goto, Kazuhiko Hashinaga, Hiroki Itoh, Kazufumi Hiramatsu, Jun-ichi Kadota.   

Abstract

BACKGROUND: Therapeutic drug monitoring (TDM) of voriconazole is important to optimize efficacy and to minimize toxicity and intolerance. In this study, we evaluated the effect of sustained high plasma trough concentration of voriconazole on the incidence of hepatotoxicity in hospitalized Japanese patients.
METHODS: Thirty-nine patients were divided into 3 groups according to trough concentrations in two consecutive TDMs: <4 μg/ml in the first TDM (group A, n=25), >4 μg/ml in the first and <4 μg/ml in the second TDM (group B, n=8), and >4 μg/ml in both first and second TDMs (group C, n=6).
RESULTS: Incidences of hepatotoxicity in groups A, B and C were 16.0, 25.0 and 83.3%, and significant differences were observed between groups A and C and groups B and C. Multiple logistic regression analysis identified the classification into groups A, B and C as an independent variable of hepatotoxicity.
CONCLUSIONS: These results suggest that sustained high trough concentration of voriconazole may increase the risk of hepatotoxicity, and decreasing trough concentration to <4 μg/ml by dose adjustment after the initial TDM may reduce the incidence of hepatotoxicity in patients treated with voriconazole.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatotoxicity; Pharmacokinetics; TDM; Therapeutic drug monitoring; Trough; Voriconazole

Mesh:

Substances:

Year:  2013        PMID: 23747486     DOI: 10.1016/j.cca.2013.05.025

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  17 in total

1.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

2.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

4.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Voriconazole and the liver.

Authors:  Romeo-Gabriel Mihăilă
Journal:  World J Hepatol       Date:  2015-07-18

6.  Antifungal Drugs Influence Neutrophil Effector Functions.

Authors:  Frederic Ries; Astrid Alflen; Pamela Aranda Lopez; Hendrik Beckert; Matthias Theobald; Hansjörg Schild; Daniel Teschner; Markus Philipp Radsak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 7.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

8.  The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.

Authors:  A G S Warrilow; C M Hull; J E Parker; E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; D E Kelly; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

9.  A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Authors:  Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

10.  Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Authors:  Lisa F Shubitz; Hien T Trinh; John N Galgiani; Maria L Lewis; Annette W Fothergill; Nathan P Wiederhold; Bridget M Barker; Eric R G Lewis; Adina L Doyle; William J Hoekstra; Robert J Schotzinger; Edward P Garvey
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.